Background/Aims: Differences in cognition between frontotemporal dementia (FTD) and Alzheimer disease (AD) are well described in clinical cohorts, but have rarely been confirmed in studies with pathologic verification. For emerging therapeutics to succeed, determining underlying pathology early in the disease course is increasingly important. Neuropsychological evaluation is an important component of the diagnostic workup for AD and FTD. Patients with FTD are thought to have greater deficits in language and executive function while patients with AD are more likely to have deficits in memory.
Objectives: To determine if performance on initial cognitive testing can reliably distinguish between patients with frontotemporal lobar degeneration (FTLD) and AD neuropathology. In addition, are there other factors of the neuropsychological assessment that can be used to enhance the accuracy of underlying pathology?
Methods: Using a logistic regression we retrospectively compared neurocognitive performance on initial evaluation of 106 patients with pathologically verified FTLD (pvFTLD), with 558 pathologically verified AD (pvAD) patients from the National Alzheimer's Coordinating Center using data from the Uniform Data Set (UDS) and the neuropathology data set.
Results: As expected, pvFTLD patients were younger, demonstrated better memory performance, and had more neuropsychiatric symptoms than pvAD patients. Other results were less predictable: pvFTLD patients performed better on one test of executive function (trail making test part B) but worse on another (digit span backward). Performance on language testing did not strongly distinguish the 2 groups. To determine what factors led to a misdiagnosis of AD in patients with FTLD, we further analyzed a small group of pvFTLD patients. These patients demonstrated older age and lower Neuropsychiatric Inventory Questionnaire counts compared with accurately diagnosed cases.
Conclusions:
Other than memory, numerical scores of neurocognitive performance on the UDS are of limited value in differentiating FTLD from AD at the initial visit. These results highlight the difficulty of obtaining an accurate early diagnosis of FTLD and argue for adding supplemental tests to those included in the UDS to assess cognition in FTD and AD patients.
Key Words: frontotemporal dementia, Alzheimer disease, pathology, neuropsychology, neuropsychiatric symptoms (Alzheimer Dis Assoc Disord 2017;31:187-191) F rontotemporal dementia (FTD) is the clinical manifestation of a number of different pathologic processes resulting in focal atrophy of the frontal or temporal lobes. The term frontotemporal lobar degeneration (FTLD) is used to capture the pathologic processes that cause the clinical syndrome of FTD. Three clinical subtypes of FTD are now strongly associated with FTLD: a behavioral variant and 2 types of primary progressive aphasia. 1 After Alzheimer disease (AD), FTLD is the second most common neuropathologic finding associated with young onset dementia. Although advances in biomarkers have improved diagnostic accuracy, the considerable phenotypic overlap that exists between AD and FTD results in a substantial percentage of patients being misdiagnosed, especially early in the disease course. 2 Currently, neuropathologic examination remains the gold standard of diagnosis for both diseases. Improving the accuracy rates of a clinical diagnosis of AD and FTD remain a significant challenge in the field of dementia given the differences in treatment, prognosis, and heritability. High misdiagnosis rates also represent a major impediment to the development of much needed molecular-based therapies.
Neuropsychological assessment is an important element of the workup used to diagnose FTD and AD. Traditionally, the neurocognitive profile of FTD is associated with early and significant impairments in language and executive functioning while AD is characterized by early deficits in episodic memory not normalized by cues. 3 Differences in the behavioral dimension associated with AD and FTD have also been described. 4 Although a number of studies have compared the neuropsychological profiles between FTD and AD in clinically diagnosed cohorts, [5] [6] [7] [8] [9] fewer studies have looked at neuropsychological testing in subjects with pathologic verification. [10] [11] [12] [13] Studies verifying clinical-pathologic correlations are greatly needed.
The National Alzheimer's Coordinating Center (NACC) database represents a unique opportunity to investigate clinical symptoms while ultimately knowing final pathology. Among many items included in the database is a Uniform Data Set (UDS) composed of a brief neuropsychological test battery (NTB) and the Neuropsychiatric Inventory Questionnaire (NPI-Q) 14 alongside other measures. In this study we retrospectively compared the results of cognitive testing and NPI-Q scores from the first clinical visit in patients with pathologically verified AD (pvAD) and pathologically verified FTLD (pvFTLD). We were also interested in determining the accuracy of an initial clinical diagnosis of FTD, and in those misdiagnosed, if certain elements of neuropsychological testing could be used to improve diagnostic accuracy. Overall, the aim of this study was to assess the ability of the UDS to differentiate these common forms of dementia at initial clinical presentation.
METHODS
The NACC serves as a data repository from >30 past and present National Institute on Aging Alzheimer Disease Centers (ADCs). Included in the NACC is a UDS that includes standardized demographic, cognitive, and behavioral information as well as a clinical diagnosis. Clinical diagnosis for each ADC patient is based on standard criteria but varies according to each ADC's diagnostic protocol. Included in the NACC is a neuropathology data set (NP) containing standardized neuropathology data. 15 The NP permits each individual site's pathologist to attribute a single "primary diagnosis" and multiple "contributing diagnosis" to each autopsied brain. The NP allows for the discretion of each ADC site in making the diagnostic attribution and does not impose that a specific criteria be used (ie, CERAD, NIA/Regan Institute, ADRDA/Khachaturian). The NACC also collects data on patients with dementias from non-AD etiologies.
For this study, neuropathologic data from the NP were cross-referenced with clinical information abstracted from the UDS. The data were from the NACC sample after initiation of the UDS in September 2005, locked in March 2014. In our sample, we included all cases of pvFTLD and pvAD who had completed the NTB battery during their initial clinical visit. In an attempt to control for dementia severity, scores on initial mini mental status examination were compared between the 2 groups. Because no significant differences were detected, all patients were included in the analysis.
UDS scores from the first clinical visit were analyzed. 14 Clinical diagnoses within the NACC are made by expert clinicans at each of the center according to published research criteria. Within the NACC coding scheme there is a code for "primary diagnosis." To define the pathologic diagnosis of our groups we started with those coded as having a primary neuropathologic diagnosis of FTLD (NACC database code NPPFTLD = 1) or AD (NACC database code = NPPAD). We excluded patients where FTLD or AD were considered "contributing diagnoses." For clinical diagnoses, we only included primary diagnoses.
Analysis Plan
We used logistic regression (LR) to assess the likelihood of each test in separating the 2 pathologic groups. Age and education were used as regressors given their potential influence on test scores. Although typically used in generating models to predict group membership, LR models can alternatively be used to simultaneously test for group differences among a set of variables when 2 groups are being compared without increasing risk of false-positive errors from multiple comparisons and with fewer underlying assumptions. 16 A LR model using pathologic diagnosis as a classification (FTLD or AD) as the outcome and raw scores of neuropsychological measures and number of symptoms endorsed on the NPI-Q as predictors, as well as, age and years of education was fit. The variables included in the analysis are included in Table 1 . Odds ratios and associated 95% confidence interval for each predictor were evaluated to determine the relative influence of each predictor on group membership.
RESULTS

Clinical Characteristics and Neurocognitive Test Performance
A total of 106 patients with pvFTLD were compared with 558 patients with pvAD. A test of the full model against a constant only model fit using the original data was significant (w 2 = 192.54; P < 0.0001, Nagelkerke R 2 = 0.41). Potential collinearity was addressed: the tolerance and variance inflation factors were acceptable. Condition indices in excess of 20 were further evaluated, and variance proportions revealed significant collinearity only between LMI and LMII. Subsequently, LMI was excluded allowing us to retain the test of delayed memory, that is, LMII.
Of the entered variables, several showed significant differences between groups in the pooled model. pvFTLD patients performed better on TMB, and LMII. pvFTLD patients performed more poorly on Digit Span Backwards, Semantic Fluency, and had a larger number of NPI-Q symptoms.
Diagnostic Accuracy
Comparisons between initial clinical diagnosis and pvFTLD and pvAD are presented in Figure 1 . When combining both language and behavioral variants, an initial clinical diagnosis of FTD accurately predicted FTLD pathology approximately 57% of the time. Overall, 18% of patients diagnosed with AD were ultimately found to have FTLD pathology. An initial clinical diagnosis of AD was found to be accurate in 70% of patients. A variety of other initial clinical diagnoses turned out to have AD pathology at autopsy.
Clinical Characteristics of Misdiagnosed pvFTLD Cases
A sizeable number of patients harboring FTLD pathology had been misdiagnosed with AD at their initial visit. To better understand the clinical characteristics that may distinguish this group from their counterparts with FTLD who were accurately diagnosed, an additional analysis was performed. When using the same LR model described above, however, only those variables that were statistically significant in the larger model were included in the analysis (age, LMII, Digit Span Backwards, Animal Fluency, TMB). Although this is admittedly underpowered, it allows for exploration of the clinical differences between accurately diagnosed and misdiagnosed patients and was thus considered important, even at the exploratory level.
In this analysis significant differences were only seen in 2 variables: (a) age-pvFTLD patients initially diagnosed clinically with AD were significantly older (mean age of 76.51 y old compared with 64.16 y old)-and (b) NPI-Q total symptom score-misdiagnosed pvFTLD patients had fewer neuropsychiatric symptoms (odds ratio, 1.37; confidence interval, 1.050-1.792; P = 0.003)-than accurately diagnosed patients.
In comparing the neuropsychiatric profile of those were accurately diagnosed compared with those who were misdiagnosed, 3 symptoms emerged as being more common in the accurately diagnosed FTLD group: aberrant motor changes (P = 0.001), apathy (P = 0.002), and delusions (P = 0.42). There were no significant differences in the frequency of appetite changes, nighttime behaviors, irritability, disinhibition, anxiety, elation, agitation, and hallucinations. No NPI-Q symptoms were more common in the misdiagnosed FTLD patients.
DISCUSSION
In the absence of definitive biomarkers, there is great interest in defining phenotypic signatures of FTLD, especially early in the disease course when molecular-based therapies are more likely to be effective. Utilizing the NACC database, this study retrospectively looked for differences in initial neuropsychological assessment in a large group of patients with later pathologic verification of either FTLD or AD. To the best of our knowledge this study represents the largest comparison of neurocognitive test performance with pathologic verification. As expected, we found that pvFTLD patients present at a younger age, report a greater number of neuropsychiatric symptoms, and perform better on memory tests than pvAD patients. Other results were less predictable with pvFTLD patients performing better on one test of executive function (TMB) and worse on another (reverse digit span). In addition, performance on language testing did not clearly separate the 2 groups. In general, with the exception of memory, the UDS did not define distinct patterns of neurocognitive performance between the 2 groups.
A number of studies have reports that AD and FTLD have different neuropsychological profiles with the most robust differences seen in executive function, 9 visuospatial abilities, 17,13 language, 10 and memory. 11, 13 In the current study we found significant differences in the expected direction only in memory. Executive measures showed more variable findings that might be expected. Performance on TMB, with pvFTLD taking less time to complete the task, showed the reverse finding than would be expected. The sensitivity of this measure in detecting executive dysfunction in FTLD is relatively unknown as it has not been widely reported in FTLD cohorts. 18 Several studies have reported that certain aspects of executive function are more severely affected than others-particularly decision making more than working memory 19, 20 -and it is possible that the tests included in UDS are not sensitive to accurately capture the executive dysfunction in FTLD. This has led some authors to advocate for characterizing performance across a full range of executive abilities and for the qualitative assessment of performance rather than simply comparing scores. 21 Despite published and validated criteria for FTD, many patients are initially misdiagnosed. In this study we found that only 57% patients with FTLD neuropathology were correctly identified as having a FTD (combining both language and behavioral variants) at their initial visit. Notably, 1 in 5 patients with FTLD were initially misdiagnosed clinically as AD. When we compared this group (ie, those misdiagnosed with AD but ultimately having FTLD neuropathology) to those who were accurately diagnosed, we found that misdiagnosed patients were significantly older (on average 12 y older) and reported fewer neuropsychiatric symptoms. Although we assumed that this group of FTLD patients presented with an AD "phenotype" (memory loss) this was not necessarily the case as both groups performed comparably on neurocognitive testing. This finding suggests that a percentage of FTLD patients present later in life and with a milder behavioral phenotype. Memory testing is likely useful in distinguishing this group from patients with underlying AD neuropathology.
This study has several limitations. First, the NACC database lacks detailed neuroanatomic information on the localization of pathologic changes. Because of this, when we analyzed neurocognitive performance of patients with FTLD, we were unable to separately assess patients with left temporal pathology from those with orbitofrontal or right temporal pathology. As a result, all patients with underlying FTLD pathology (whether or not they presented with a language or behavioral variant phenotype) were analyzed together. This is important because it is likely that specific network disruption rather than the type of cellular change that drives phenotypic expression. Second, the concept of primary progressive aphasias have evolved significant during the period of data collection. Three variants of primary progressive aphasia are now recognized, including 1 variant-the logopenic form of primary progressive aphasia-that is typically caused by AD. Patients diagnosed with logopenic aphasia are coded as "PPAOTHR" in the NACC database, a clinical criteria that also includes other language descriptions such as "anomic." Consequently, we were unable to analyze patients initially diagnosed with logopenia as part of the AD group. On the basis of the small number of patients diagnosed with "PPAOTHR" this is unlikely to have had a significant impact on our results. Finally, new staining techniques for FTLD have greatly improved over the past 5 years. In particular, pathologists are much better able to characterize the tau negative forms (TDP-43 and FUS varieties) that cause about 50% of all FTLD cases. This study utilized analyzed retrospective data from the NP database that, in many cases did not have access to these newer staining techniques.
Forthcoming research involving FTD, including analysis of the NACC FTLD module that was introduced in 2012 adding pathologic data in 2014, may overcome many of the limitations of the current study, including providing more thorough clinical description and updated pathologic definition. For now, emphasis in both clinical and research settings on adding supplemental tests to those included in the UDS to assess cognition in FTD and AD patients, and continued emphasis on behavioral measures will be important in attempting to optimize the diagnosis of and research into these 2 common forms of dementia.
